Trevi Therapeutics announced the completion of enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). This marks a significant operational milestone for the company.
Topline results from the CORAL trial continue to be expected in the first half of 2025. The study is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio against placebo over a six-week period.
Approximately 160 IPF patients with chronic cough were randomized in the trial. The primary efficacy endpoint is the relative change in 24-hour cough frequency at Week 6 versus baseline, as measured by an objective cough monitor.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.